Understand the source comparison
Peptides vs Physical Therapy: Clinical Comparison
BPC-157 Peptide Upregulates VEGF, promotes angiogenesis, increases fibroblast migration Inflammatory and proliferative phases (days 0–21) Preclinical studies; limited human RCTs 7–14 days for measurable tissue changes Accelerates tissue healing; does not resto
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 Peptide
- Upregulates VEGF, promotes angiogenesis, increases fibroblast migration
- Inflammatory and proliferative phases (days 0–21)
- Preclinical studies; limited human RCTs
- 7–14 days for measurable tissue changes
- Accelerates tissue healing; does not restore movement patterns
- Strongest evidence for soft tissue repair; requires PT for functional integration
- TB-500 Peptide
- Promotes actin polymerisation, reduces fibrosis, enhances myoblast migration
- Proliferative phase (days 7–28)
- Preclinical models; observational human case series
- 10–21 days for improved contractile capacity
- Reduces scar tissue formation; improves tissue elasticity
- Effective for muscle injuries; limited direct effect on joint mechanics
- Eccentric Loading PT
- Mechanotransduction stimulates collagen realignment and tenocyte proliferation
- Remodelling phase (days 21+)
- Multiple RCTs; systematic review support
- 4–12 weeks for functional strength gains
- Restores biomechanical function and movement quality
- Gold standard for tendinopathy; requires adequate tissue integrity to tolerate load
- Neuromuscular Re-education PT
- Rebuilds proprioception and motor control through progressive movement complexity
- Remodelling and return-to-sport phases
- Strong clinical consensus; RCT support in ACL rehab
- 6–16 weeks for movement pattern correction
- Prevents compensatory movement and re-injury
- Essential for athletes; peptides do not address motor control deficits